Segmentation: Global Blood Screening Market

Global blood screening market is categorized based on basis of products & services, technology, disease type and end user.

On the basis of product & services the market is segmented into reagents and kits, instruments and software & services. Reagents and kits are further sub segmented into NAT reagents & kits, ELISA reagents & kits others as well. NAT reagents is further sub segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions alsolabeling and detection reagents. ELISA reagents & kits is further sub segmented into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) also sample diluents and wash solutions. Instruments segment is further segmented into instruments, product types and instruments, purchase type. In 2017, reagents & kits segment is expected to dominate the global blood screening market growing at the CAGR of 9.4% in the forecast period of 2018 to 2025.

In September 2018, Thermo Fisher Scientific Inc. (U.S.), signed a definitive agreement with BD This business combines a strong technical service program with a variety of media and other products. This acquisition helped company to expand their business on global level with larger number of products.
On the basis of disease type, the market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold & flu, infectious diseases and others. In 2017, oncology segment is expected to dominate the global blood screening marketgrowing at the highest CAGR of 10.3% in the forecast period of 2018 to 2025.

READ MORE @https://databridgemarketresearch.com/reports/global-blood-screening-market/

Competitive Analysis: Global Blood Screening Market

Some of the prominent participants operating in this market are Enzo Biochem Inc., Meridian Bioscience, Inc. , BD , Bio-Rad Laboratories, Inc. , Thermo Fisher Scientific Inc.

Product launch:

In March 2018, Bio-Rad Laboratories, Inc. launched IncRNA Workflow, a RT-qPCR workflow which is used to optimized for highly sensitive and specific quantification of long noncoding RNAs (lncRNAs) for gene expression analysis. The workflow provides a streamlined, cost-effective alternative to RNA-Seq for lncRNA discovery and validation.

In June 2018, Thermo Fisher Scientific launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.

Contact:

Data Bridge Market Research

Office Number 402, Amanora Chambers

Magarpatta Road, Hadapsar Pune – 411028

Tel: +1-888-387-2818

Email: [email protected]

Blog@ https://databridgemarketresearch.com/blog/